Skip to content

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05911711
Enrollment
120
Registered
2023-06-22
Start date
2023-07-07
Completion date
2024-06-07
Last updated
2023-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

Sepsis, a severe response to bacterial infection, lacks understanding of immunometabolic features that can identify high-risk patients. This study aimed to discover immune, biological, and metabolic biomarkers in sepsis patients with poor prognosis and understand the underlying mechanisms of host immune responses.

Detailed description

Sepsis is a life-threatening condition resulting from a dysregulated host response to infection and remains a significant global health crisis. Accurately identifying high-risk patients and understanding the underlying mechanisms of distinct host responses are crucial. Dysregulation of immune and biological responses, along with metabolic remodeling, has emerged as a prevalent characteristic in sepsis patients. However, there is still a need for a comprehensive understanding of specific markers related to immunometabolism and the underlying mechanisms contributing to the disturbance in sepsis pathogenesis. This study aims to investigate the immune, biological, and metabolic profiles of sepsis patients, focusing on the alteration of metabolism in sepsis patients with poor outcomes. The findings of this study will provide valuable insights into dysregulated immunometabolism, shedding light on its contribution to the potentiation of immunopathogenesis in sepsis. Eligibility Criteria adults over the age of 19 a sepsis patient in ICU Patients are excluded from the study If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation(DNR) patient a patient under the age of 18 Outcome Measure ICU mortality, 28 days mortality Use of inotropics, vasopressors CRRT(continuous renal replacement therapy), ECMO (Extracorporeal membrane oxygenation), Interventional lung assist, polymyxin

Interventions

OTHERPrognostic factor

normal person (no sepsis group)

Sponsors

Chungnam National University
CollaboratorOTHER
Chungnam National University Hospital
CollaboratorOTHER
Kangdong Sacred Heart Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adults over the age of 19 a sepsis patient in ICU

Exclusion criteria

* If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a DNR patient a patient under the age of 18

Design outcomes

Primary

MeasureTime frameDescription
up to 1 day ICU mortalityup to 1 day ICU mortalityup to 1 day ICU mortality

Secondary

MeasureTime frameDescription
28 days mortality28 days mortality28 days mortality

Countries

South Korea

Contacts

Primary ContactSo Young Park, doctor
sy.park12@gmail.com+8201052058637
Backup ContactEun-Kyeong Jo, doctor
hayoungj@cnu.ac.kr+8201047628243

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026